Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
1. Centers for Disease Control and Prevention. National Diabetes Statistics Report. Available at https://www.cdc.gov/diabetes/php/data-research/index.html. Last accessed November 3, 2025.
2. Centers for Disease Control and Prevention. About the Division of Diabetes Translation. Available at https://www.cdc.gov/nccdphp/divisions-offices/about-the-division-of-diabetes-translation.html?CDC_AAref_Val=https://www.cdc.gov/chronicdisease/resources/publications/aag/diabetes.htm. Last accessed November 3, 2025.
3. Dall TM, Zhang Y, Chen YJ, Quick WW, Yang WG, Fogli J. The economic burden of diabetes. Health Aff (Millwood). 2010;29(2):297-303.
4. American Diabetes Association. New American Diabetes Association Report Finds Annual Costs of Diabetes to be $412.9 Billion. Available at https://diabetes.org/newsroom/press-releases/new-american-diabetes-association-report-finds-annual-costs-diabetes-be. Last accessed November 3, 2025.
5. Davis J, Fischl AH, Beck J, et al. 2022 National standards for diabetes self-management education and support. Diabetes Care. 2022;45(2):484-494.
6. American Diabetes Association. Standards of care in diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S1-S344.
7. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
8. American Diabetes Association. Implications of the United Kingdom prospective diabetes study. Diabetes Care. 2002;25(Suppl 1):S28-S32.
9. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. Circulation. 2009;119(2):351-357.
10. American Diabetes Association. Statistics About Diabetes. Available at https://diabetes.org/about-diabetes/statistics/about-diabetes. Last accessed November 3, 2025.
11. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290(14):1884-1890.
12. Fradkin J, Rodgers GP. The economic imperative to conquer diabetes. Diabetes Care. 2008;31(3):624-625.
13. National Indian Council on Aging, Inc. Diabetes Still Highest Among AI/AN. Available at https://www.nicoa.org/diabetes-still-highest-among-ai-an/#. Last accessed November 3, 2025.
14. Roberts H, Jiles R, Mokdad A, Beckles G. Rios-Burrows N. Trend analysis of diagnosed diabetes prevalence among American Indian/Alaska Native young adults—United States, 1994–2007. Ethnicity Disease. 2009;19:276-279.
15. U.S. Department of Health and Human Services, Office of Minority Health. Diabetes and Black/African Americans. Available at https://minorityhealth.hhs.gov/diabetes-and-blackafrican-americans. Last accessed November 3, 2025.
16. U.S. Department of Health and Human Services, Office of Minority Health. Diabetes and Hispanic/Latino Americans. Available at https://minorityhealth.hhs.gov/diabetes-and-hispaniclatino-americans. Last accessed November 3, 2025.
17. U.S. Department of Health and Human Services, Office of Minority Health. Diabetes and Asian Americans. Available at https://minorityhealth.hhs.gov/diabetes-and-asian-americans. Last accessed November 3, 2025.
18. LexiDrug. Available at https://online.lexi.com/lco/action/login. Last accessed November 3, 2025.
19. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013;36(Suppl 2):S127-S138.
20. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
21. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med. 2002;346(6):393-403.
22. National Diabetes Prevention Program. Preventing Type 2 Diabetes with the Lifestyle Change Program. Available at https://www.cdc.gov/diabetes-prevention/lifestyle-change-program/?CDC_AAref_Val=https://www.cdc.gov/diabetes/prevention/why-participate.html. Last accessed November 3, 2025.
23. National Institute of Diabetes and Digestive and Kidney Diseases. Pancreatic Islet Transplantation. Available at https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments/pancreatic-islet-transplantation. Last accessed November 3, 2025.
24. American Diabetes Association. Gestational Diabetes. Available at https://www.diabetes.org/diabetes/gestational-diabetes. Last accessed November 3, 2025.
25. Centers for Disease Control and Prevention. Diabetes Risk Factors: Gestational Diabetes. Available at https://www.cdc.gov/diabetes/risk-factors/?CDC_AAref_Val=https://www.cdc.gov/diabetes/basics/risk-factors.html. Last accessed November 3, 2025
27. Noctor E, Crowe C, Carmody LA, et al. Abnormal glucose tolerance post-gestational diabetes mellitus as defined by the International Association of Diabetes and Pregnancy Study Groups criteria. Eur J Endocrinol. 2016;175:287-297.
28. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002;25:1862-1868.
29. American Diabetes Association. How to Treat Gestational Diabetes. Available at https://diabetes.org/living-with-diabetes/pregnancy/gestational-diabetes/how-to-treat-gestational-diabetes. Last accessed November 3, 2025.
30. American Diabetes Association. Diabetes and DKA (Ketoacidosis). Available at https://diabetes.org/about-diabetes/complications/ketoacidosis-dka/dka-ketoacidosis-ketones. Last accessed November 3, 2025.
31. Centers for Disease Control and Prevention. Diabetic Ketoacidosis. Available at https://www.cdc.gov/diabetes/about/diabetic-ketoacidosis.html?CDC_AAref_Val=https://www.cdc.gov/diabetes/basics/diabetic-ketoacidosis.html. Last accessed November 3, 2025.
32. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335-1343.
33. Davidson MB, Scwartz S. Hyperglycemia. In: Franz MJ (ed). A Core Curriculum for Diabetes Education: Diabetes and Complications. 5th ed. Chicago, IL: American Association of Diabetes Educators; 2003.
34. American Diabetes Association. Economic costs of diabetes in the U.S. in 2022. Diabetes Care. 2022;47(1):26-43.
35. Centers for Disease Control and Prevention. Diabetes Complications. Available at https://www.cdc.gov/diabetes/complications/?CDC_AAref_Val=https://www.cdc.gov/diabetes/managing/problems.html. Last accessed November 3, 2025.
36. National Institute of Diabetes and Digestive and Kidney Diseases. Blood Glucose Control Studies for Type 1 Diabetes: DCCT and EDIC. Available at https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/blood-glucose-control-studies-type-1-diabetes-dcct-edic. Last accessed November 3, 2025.
37. Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in U.S. adults, 1999-2018. New Engl J Med. 2021;384:2219-2228.
39. Sharma AM, Weir MR. The role of angiotensin receptor blockers in diabetic nephropathy. Postgrad Med. 2011;123(3):109-121.
40. Mayo Clinic. Diabetic Neuropathy. Available at https://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/symptoms-causes/syc-20371580#. Last accessed November 3, 2025.
41. Dal Canto E, Ceriello A, Ryden L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Preventive Cardiol. 2019;26(2):25-32.
42. Kearney PM, Blackwell L, Collins R, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomized trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-125.
43. Polonsky WH. Diabetes Burnout: What to Do When You Can't Take It Anymore. Alexandria, VA: American Diabetes Association; 1999.
44. Rubin RR, Napora JP. Psychosocial assessment. In: Franz MJ (ed). A Core Curriculum for Diabetes Education: Diabetes and Complications. 5th ed. Chicago, IL: American Association of Diabetes Educators; 2003.
45. Prochaska JO, DiClemente CC. Common processes of self-change in smoking, weight control, and psychological distress. In: Shiffman S (ed). Coping and Substance Abuse: A Conceptual Framework. New York, NY: Academic Press; 1985: 345-363.
47. Duncan I, Birkmeyer C, Coughlin S, Li QE, Sherr D, Boren S. Assessing the value of diabetes education. Diabetes Educ. 2009;35(5):752-760.
48. U.S. Department of health and Human Services. Healthy People 2030. Available at https://health.gov/healthypeople. Last accessed November 3, 2025.
49. Centers for Disease Control and Prevention. Diabetes Self-Management Education and Support. [Archive]. Available at https://archive.cdc.gov/#/details?q=https://www.cdc.gov/diabetes/library/reports/reportcard/diabetes-self-management-education-support.html&start=0&rows=10&url=https://www.cdc.gov/diabetes/library/reports/reportcard/diabetes-self-management-education-support.html. Last accessed November 3, 2025.
50. International Diabetes Federation. IDF Global Clinical Practice Recommendations for managing Type 2 Diabetes 2025. Available at https://idf.org/media/uploads/2025/04/IDF_Rec_2025.pdf. Last accessed November 3, 2025.
51. Martin S, Schneider B, Heinnemann L, et al. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia. 2006;49(2):271-278.
52. Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA. 2006;295(14):1688-1697.
53. Malanda UL, Welschen LMC, Riphagen II, Dekker JM. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev. 2012;(1):CD005060.
54. DTS Blood Glucose Monitoring System Surveillance Program. Available at https://www.diabetestechnology.org/surveillance.shtml. Last accessed November 3, 2025.
55. American Diabetes Association. Check Your Blood Glucose: Diabetes Testing and Monitoring. Available at https://diabetes.org/living-with-diabetes/treatment-care/checking-your-blood-sugar. Last accessed November 3, 2025.
56. Cox DJ, Taylor AG, Moncrief M, et al. Continuous glucose monitoring in the self-management of type 2 diabetes: a paradigm shift. Diabetes Care. 2016;39(5):e71-e73.
57. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Pediatric Use of Dexcom's G4 Platinum Continuous Glucose Monitoring System. Available at https://wayback.archive-it.org/7993/20170112222919/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm384495.htm. Last accessed November 3, 2025.
58. Kapstone Medical. Resource Center. FDA Approves First Continuous Glucose Monitoring System Not Requiring Blood Sample Calibration. Available at https://www.kapstonemedical.com/resource-center/blog/fda-approves-first-continuous-glucose-monitoring-system-not-requiring-blood-sample-calibration. Last accessed November 3, 2025.
59. Abbott. Abbott's Freestyle Libre 2 ICGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards. Available at https://abbott.mediaroom.com/2020-06-15-Abbotts-FreeStyle-R-Libre-2-iCGM-Cleared-in-U-S-for-Adults-and-Children-with-Diabetes-Achieving-Highest-Level-of-Accuracy-and-Performance-Standards. Last accessed November 3, 2025.
60. Black E. Abbott Has a New Glucose Monitor for Diabetics – It's So Small I Forgot I Was Wearing It. Available at https://www.cnbc.com/2022/10/14/review-abbott-freestyle-libre-3-cgm-for-diabetics-.html. Last accessed November 3, 2025.
61. Tucker ME. FDA Approves New 'Smart' Continuous Glucose Monitor for Diabetes. Available at https://www.medscape.com/viewarticle/893851. Last accessed November 3, 2025.
62. PR Newswire. FDA Authorizes First Fully Interoperable Continuous Glucose Monitoring System, Streamlines Review Pathway for Similar Devices. Available at https://www.prnewswire.com/news-releases/fda-authorizes-first-fully-interoperable-continuous-glucose-monitoring-system-streamlines-review-pathway-for-similar-devices-300620505.html. Last accessed November 3, 2025.
63. U.S. Food and Drug Administration. Eversense E3 Continuous Glucose Monitoring (CGM) System – P160048/S021. Available at https://www.fda.gov/medical-devices/recently-approved-devices/eversense-e3-continuous-glucose-monitoring-cgm-system-p160048s021. Last accessed November 3, 2025.
64. Cardiometabolic Health Congress. FDA Approves First Year-Long Continuous Glucose Monitoring Sensor for Diabetes. Available at https://www.cardiometabolichealth.org/fda-approves-first-year-long-continuous-glucose-monitoring-sensor-for-diabetes. Last accessed November 3, 2025.
65. U.S. Food and Drug Administration. FDA News Release: FDA Clears First Over-the-Counter Continuous Glucose Monitor. Available at https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor#. Last accessed November 3, 2025.
66. Doyle-Delgado K, Chamberlain JJ. Use of diabetes-related applications and digital health tools by people with diabetes and their health care providers. Clin Diabetes. 2020;38(5):449-461.
67. American Diabetes Association. A1C and eAG. Available at https://diabetes.org/a1c-eag-conversion-calculator. Last accessed November 3, 2025.
68. GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1345-1422.
69. Pan A, Lin X, Hemler E, Hu FB. Diet and cardiovascular disease: advances and challenges in population-based studies. Cell Metab. 2018;27(3):489-496.
70. Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet. 2014;383(9933):1999-2007.
71. Joslin Diabetes. What Impacts Glucose Levels in Your Diet. Available at https://www.joslin.org/patient-care/diabetes-education/diabetes-learning-center/what-impacts-glucose-levels-your-diet. Last accessed November 3, 2025.
72. American Diabetes Association, Bantle JP, Wylie-Rosett J, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008;31(Suppl 1):S61-S78.
73. Morris SF, Wylie-Rosett J. Medical nutrition therapy: a key to diabetes management and prevention. Clinical Diabetes. 2010;28(1):12-18.
74. Franz MJ, Powers MA, Leontos C, et al. The evidence for medical nutrition therapy for type 1 and type 2 diabetes in adults. J Am Diet Assoc. 2010;110(12):1852-1889.
75. DGA. Dietary Guidelines for Americans, 2020-2025 and Online Materials. Available at https://www.dietaryguidelines.gov/resources/2020-2025-dietary-guidelines-online-materials. Last accessed November 3, 2025.
76. U.S. Department of Agriculture MyPlate. Eat Healthy With MyPlate. Available at https://www.myplate.gov/. Last accessed November 3, 2025.
77. American Diabetes Association. Nutrition for Life: Diabetes Plate Method. Available at https://professional.diabetes.org/sites/dpro/files/2023-12/plan_your_plate.pdf. Last accessed November 3, 2025.
78. Evert AB, Boucher JL, Cypress M, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care. 2013;36(11):3821-3842.
79. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019;42(5):731-754.
80. Mayo Clinic. Tips for Prediabetes and Diabetes Meal Planning. Available at https://newsnetwork.mayoclinic.org/discussion/tips-for-prediabetes-and-diabetes-meal-planning/. Last accessed November 3, 2025.
81. Pedersen SD, Kang J, Kline GA. Portion control plate for weight loss in obese patients with type 2 diabetes mellitus: a controlled clinical trial. Arch Intern Med. 2007;167(12):1277-1283.
82. Rizor H, Smith M, Thomas K, Harker J, Rich M. Have you tried the Idaho plate method? DCE Newsflash. 1996;17:18-20.
84. University of Idaho. Healthy Diabetes Plate, 2nd Edition. Available at https://marketplace.uidaho.edu/C20272_ustores/web/product_detail.jsp?PRODUCTID=2675. Last accessed November 3, 2025.
85. Idaho Plate Method. Plate Method. Available at http://www.platemethod.com. Last accessed November 3, 2025.
86. Seagle HM, Strain GW, Makris A, Reeves RS, American Dietetic Association. Position of the American Dietetic Association: weight management. J Am Diet Assoc. 2009;109(2):330-346.
87. American Diabetes Association. Non-Starchy Vegetables for Blood Glucose Control. Available at https://diabetes.org/food-nutrition/reading-food-labels/non-starchy-vegetables. Last accessed November 3, 2025.
88. American Diabetes Association. Oral and Injectable Medications for Type 2 Diabetes. Available at https://diabetes.org/health-wellness/medication/oral-other-injectable-diabetes-medications. Last accessed November 3, 2025.
89. Joslin Diabetes Center. Clinical Guideline for Management of Adults with Diabetes. Available at https://joslin.org/-/media/files/joslin/joslin-clinical-guidelines-for-management-of-adults-with-diabetes.pdf. Last accessed November 3, 2025.
90. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443.
91. GlaxoSmithKline. Highlights of Prescribing Information: Avandia. Available at https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Avandia/pdf/AVANDIA-PI-MG.PDF. Last accessed November 3, 2025.
92. Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs: insights from the rosiglitazone experience. NEJM. 2013;369(14):1285-1287.
94. Wallach JD, Wang K, Zhang AD, et al. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ. 2020;368:I7078.
95. U.S. Food and Drug Administration. FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to Restrict Access to Rosiglitazone-containing Medicines including Avandia, Avandamet, and Avandaryl. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-risk-evaluation-and-mitigation-strategy-rems-restrict-access. Last accessed November 3, 2025.
96. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Requires Removal of Some Prescribing and Dispensing Restrictions for Rosiglitazone-containing Diabetes Medicines. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-requires-removal-some-prescribing-and-dispensing-restrictions. Last accessed November 3, 2025.
97. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Eliminates the Risk Evaluation and Mitigation Strategy (REMS) for Rosiglitazone-Containing Diabetes Medicines. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-eliminates-risk-evaluation-and-mitigation-strategy-rems. Last accessed November 3, 2025.
99. Daily Med. Available at https://dailymed.nlm.nih.gov/dailymed/index.cfm. Last accessed October 15, 2025.
100. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Tanzeum to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023843/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393289.htm. Last accessed November 3, 2025.
101. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Trulicity to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023822/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm415180.htm. Last accessed November 3, 2025.
102. U.S. Pharmacist. FDA Approves First Oral GLP-1 for Use in Type 2 Diabetes. Available at https://www.uspharmacist.com/article/fda-approves-first-oral-glp1-for-use-in-type-2-diabetes. Last accessed November 3, 2025.
103. U.S. Food and Drug Administration. Highlights of Prescribing Information. Rybelsus (semaglutide). Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf. Last accessed November 3, 2025.
104. U.S. Food and Drug Administration. Archive: FDA Drug Safety Podcast. FDA Investigating Reports of Possible Increased Risk of Pancreatitis and Pre-Cancerous Findings of the Pancreas from Incretin Mimetic Drugs for Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170722185812/https://www.fda.gov/Drugs/DrugSafety/ucm343187.htm. Last accessed November 3, 2025.
105. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin 4) on glycemic control and weight over 30 weeks in sulfonylurea treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
106. Campbell RK, Miller S. New therapeutic horizons: mapping the future of glycemic control with incretin-based therapies. Diabetes Educ. 2009;35(5):731-734, 738-740, 742-744.
107. Merck & Co. Medication Guide: Januvia. Available at https://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_mg.pdf. Last accessed November 3, 2025.
108. Bristol-Myers Squibb. Onglyza. Available at https://www.onglyza.com. Last accessed November 3, 2025.
109. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Three New Drug Treatments for Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023907/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336942.htm. Last accessed November 3, 2025.
110. DailyMed. SymlinPen. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff. Last accessed November 3, 2025.
111. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Invokana to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023858/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm. Last accessed November 3, 2025.
112. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Farxiga to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023850/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm. Last accessed November 3, 2025.
113. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Jardiance to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023827/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407637.htm. Last accessed November 3, 2025.
114. Pfizer. FDA Approves SGLT2 Inhibitor STEGLATRO (ertugliflozin) and Fixed-Dose Combination STEGLUJAN (ertugliflozin and sitagliptin) for Adults with Type 2 Diabetes. Available at https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_sglt2_inhibitor_steglatro_ertugliflozin_and_fixed_dose_combination_steglujan_ertugliflozin_and_sitagliptin_for_adults_with_type_2_diabetes. Last accessed November 3, 2025.
115. U.S. Food and Drug Administration. Archive: Safety Announcement. FDA Warns about Rare Occurrences of a Serious Infection of the Genital Area with SGLT2 Inhibitors for Diabetes. Available at https://wayback.archive-it.org/7993/20190207173939/https://www.fda.gov/Drugs/DrugSafety/ucm617360.htm. Last accessed November 3, 2025.
116. Fonseca V. Oxford American Endocrinology Library: Improving Patient Care. New York, NY: Oxford University Press; 2009.
117. American Diabetes Association. Low Blood Glucose (Hypoglycemia). Available at https://diabetes.org/living-with-diabetes/hypoglycemia-low-blood-glucose. Last accessed November 3, 2025.
118. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves Afrezza to Treat Diabetes. Available at https://wayback.archive-it.org/7993/20170112222845/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403122.htm. Last accessed November 3, 2025.
119. U.S. Food and Drug Administration. Highlights of Prescribing Information. Afrezza. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022472lbl.pdf. Last accessed November 3, 2025.
120. American Diabetes Association. Insulin administration. Diabetes Care. 2003;26(Suppl 1):S121-S124.
121. American Diabetes Association. Insulin Storage and Syringe Safety. Available at https://diabetes.org/health-wellness/medication/insulin-storage-and-syringe-safety. Last accessed November 3, 2025.
122. American Diabetes Association. Devices and Technology: Better Blood Glucose Meters and More. Available at https://diabetes.org/about-diabetes/devices-technology. Last accessed November 3, 2025.
123. U.S. Food and Drug Administration. Archive: Press Release. FDA Approves First Automated Insulin Delivery Device for Type 1 Diabetes. Available at https://wayback.archive-it.org/7993/20170111083713/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm522974.htm. Last accessed November 3, 2025.
124. Medtronic. The MiniMed 770G System Discontinuation. Available at https://www.medtronicdiabetes.com/products/minimed-770g-insulin-pump-system. last accessed November 3, 2025.
125. Medtronic. Minimed. Available at https://www.medtronicdiabetes.com/products/minimed-780g-insulin-pump-system. last accessed November 3, 2025.
126. American Diabetes Association. Continuous subcutaneous insulin infusion. Diabetes Care. 2004;27(Suppl 1):S110.
127. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and 2 diabetes: a position statement from the American Diabetes Association. Diabetes Care. 2016;39(11):2065-2079.
128. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007;39(8):1423-1434.
129. Mavros Y, Kay S, Anderberg KA, et al. Changes in insulin resistance and HbA1c are related to exercise-mediated changes in body composition in adults with type 2 diabetes: interim outcomes from the GREAT2DO trial. Diabetes Care. 2013;36(8):2372-2379.
130. McDermott K, Fang M, Boulton AJM, Selvin E, Hicks CW. Etiology, epidemiology, and disparities in the burden of diabetic foot ulcers. Diabetes Care. 202346(1):209-221.
132. American Diabetes Association. Preventive foot care in diabetes. Diabetes Care. 2004;27(Suppl 1):S63-S64.
133. Bronze MS. Diabetic Foot Infections. Available at https://emedicine.medscape.com/article/237378-overview. Last accessed November 3, 2025.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.